Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown
Generic net sales reflect strong growth from new product performance in Developed Markets, continued growth from complex products, and solid performance across the broader European portfolio. Generic sales fell 2% to $1.38 billion.Viatris Inc. (NASDAQ:VTRS) reported third-quarter 2024 total net sales of $3.74 billion. That's down 5%, beating the consensus of $3.71 billion, but up about 3% on a divestiture-adjusted operational basis compared to third-quarter 2023 results.
Viatris公司（納斯達克：VTRS）報告2024年第三季度總淨銷售額爲37.4億美元。較去年同期下降5％，超過了37.1億美元的共識，但與2023年第三季度相比，在調整後的出售業務基礎上增長約3％。
The company reported divestiture-adjusted operational net sales growth across all segments.
該公司報告了在所有板塊的出售業務增長中進行了調整。
Brands net sales reflect the expansion of the company's portfolio in emerging markets and JANZ, as well as strong growth in Europe and Greater China. This was partially offset by unfavorable channel dynamics in North America and the impact of government price regulations in Japan and Australia. Brand sales fell 7% to $2.36 billion.
品牌銷售反映了該公司在新興市場和JANZ以及歐洲和大中華地區組合擴大，以及歐洲和大中華地區的強勁增長。這在一定程度上被北美地區的不利渠道動態和日本以及澳洲的政府價格管制的影響部分抵消。品牌銷售下降了7％，至23.6億美元。
Generic net sales reflect strong growth from new product performance in Developed Markets, continued growth from complex products, and solid performance across the broader European portfolio. Generic sales fell 2% to $1.38 billion.
通用藥品銷售反映了在發達市場中新產品表現強勁，複雜產品持續增長，以及整個歐洲組合的出色表現。通用銷售下降了2％，至13.8億美元。
The company generated approximately $133 million in new product revenues, primarily driven by Breyna, lisdexamfetamine, and other new products globally.
該公司產生了約13300萬美元的新產品收入，主要得益於全球Breyna、利斯達莫非丁等新產品。
The company reported adjusted EPS of 75 cents, down 5% year over year, beating the consensus of 68 cents.
該公司報告的調整後每股收益爲75美分，同比下降了5％，超過了68美分的共識。
"We continue to make excellent progress executing on our debt paydown commitment and are on pace to achieve our long-term gross leverage target of ~3.0x by year-end," said Viatris CFO Doretta Mistras.
「我們在執行我們的償還債務承諾方面取得了卓越的進展，並計劃在年底前實現我們的長期毛槓桿率目標約爲3.0倍，」 Viatris首席財務官多莉塔·米斯特拉斯表示。
The company retired all of its 2025 and more than a quarter of its 2026 debt maturities, totaling approximately $1.9 billion in debt. That includes the make-whole call of its 2025 notes that settled in October.
公司償還了其所有2025年到期債務和超過四分之一的2026年到期債務，總額約爲19億美元。其中包括其2025年票據的提前還清，該交易定於10月結算。
Guidance: Viatris expects to deliver approximately $500 million to $600 million in new product revenues in 2024.
指引：viatris預計2024年新產品收入將達到$60000萬。
The company reaffirms 2024 sales of $14.6 billion – $15.1 billion versus consensus of $14.80 billion.
公司重申2024年銷售額爲$146-151億，而市場預期爲$148億。
The company expects 2024 adjusted EPS of $2.56-$2.71 compared to prior guidance of $2.58–$2.73 and the consensus of $2.67.
公司預計2024年調整後每股收益爲$2.56-$2.71，而之前的指引爲$2.58-$2.73，市場預期爲$2.67。
Price Action: Viatris stock is up 13.9% at $13.22 at last check Thursday.
股價走勢：viatris股價週四最後一次檢查報價爲$13.22，上漲了13.9%。
- Dentsply Sirona Stock Sinks On Dismal 2024 Guidance, Blames Macroeconomic, Competitive Pressures And Weakened Demand
- 登士柏股票因2024年不佳的指導下跌，責怪宏觀經濟、競爭壓力和需求疲軟
譯文內容由第三人軟體翻譯。
